The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout ... and RA Capital among its notable investors. Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor ...

Embedding the patient voice into the DNA of a pharmaceutical company ... VP and country medical director, UK and Ireland at GSK, which has a dedicated Patients in Partnership team working to ...

GSK's severe ... at a future medical congress, but is strong enough to warrant discussions with regulators about extending the indications for Nucala, according to the pharma group.

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

India's GlaxoSmithKline Pharmaceuticals ... deals with Pfizer worth a combined $897 million to manufacture products for the U.S. pharmaceutical giant. Samsung Biologics unveils $897 million ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

GlaxoSmithKline Pharmaceuticals Ltd on Friday reported a 37.87 per cent rise in consolidated net profit at Rs 182.33 crore in the first quarter ended June 30, 2024. The company had posted a ...